World News
-
Global Initiative establishes dedicated Mpox vaccine reserve to aid rapid response
The new stockpile builds on the Access and Allocation Mechanism established in 2024 during the mpox Public Health Emergency of International Concern (PHEIC).
-
WHO issues emergency guidance on Ervebo use during Bundibugyo virus outbreaks
The guidance recommends that Ervebo® should currently be used against Bundibugyo virus (BDBV) only within a research protocol.
-
AusperBio raises US$120M to advance Hepatitis B therapies toward functional cure
AusperBio will use a significant portion of the proceeds to advance AHB 137, an antisense oligonucleotide therapy for CHB, through its Phase III registrational programme and toward potential commercialisation.
-
FDA accepts Kowa’s K-911 glaucoma eye drop application for review
Kowa is seeking approval based on results from the pivotal Phase III Mont Blanc and Denali trials.
-
GE HealthCare obtains CE mark for Photonova Spectra Photon Counting CT System
Photonova Spectra uses the company’s Deep Silicon detector technology to produce high-definition images while providing spectral and spatial imaging capabilities.
-
Lundbeck’s Asedebart gains EU Orphan Designation for Cushing’s Syndrome
Cushing’s syndrome of endogenous origin occurs when the body produces excessive amounts of cortisol and other steroid hormones.
-
Amyl Therapeutics raises US$9.4M to advance amyloid disease treatment toward clinical development
Amyl Therapeutics will expand its laboratory facilities at the LegiaPark life sciences campus in Liège, Belgium, to accommodate its growing research programme.
-
Eli Lilly expands immunology footprint with US$2.88B acquisition of Merida Biosciences
The acquisition will give Lilly access to Merida’s technology for developing biologics that selectively eliminate disease-causing autoantibodies.
-
Priovant launches Lisraya in US following historic FDA approval for dermatomyositis
The decision follows positive results from the Phase III VALOR trial (NCT05437263), which showed that Lisraya improved several measures of dermatomyositis disease activity.
-
Bristol Myers Squibb’s RayzeBio to build US$173M radiopharmaceutical facility in Indiana
The new site will complement RayzeBio’s existing 77,000-square-foot radiopharmaceutical manufacturing facility in Indianapolis, located about 20 miles southwest of Whitestown.